ClinicalTrials.gov
ClinicalTrials.gov Menu

The Role Of Omega-3 Fatty Acids In Adolescent Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00962598
Recruitment Status : Completed
First Posted : August 20, 2009
Results First Posted : May 24, 2017
Last Update Posted : April 24, 2018
Sponsor:
Collaborator:
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Vilma Gabbay, Icahn School of Medicine at Mount Sinai

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Depressive Disorder, Major
Interventions: Drug: Omega 3 Fatty Acids
Dietary Supplement: Corn oil

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment began in December 2005, with enrollment from January 2006 to June 2013. Participants recruited for this imaging from another study, GCO 12-1321.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Corn Oil Corn oil: The dosage correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment. Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.
Omega-3 Fatty Acids

The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d.

Omega 3 Fatty Acids: The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.


Participant Flow:   Overall Study
    Corn Oil   Omega-3 Fatty Acids
STARTED   7   9 
COMPLETED   7   9 
NOT COMPLETED   0   0 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Corn Oil

The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment.

Corn oil: The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment. Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.

Omega-3 Fatty Acids

The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d.

Omega 3 Fatty Acids: The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.

Total Total of all reporting groups

Baseline Measures
   Corn Oil   Omega-3 Fatty Acids   Total 
Overall Participants Analyzed 
[Units: Participants]
 7   9   16 
Age 
[Units: Years]
Mean (Standard Deviation)
 16.62  (3.087)   16.51  (2.756)   16.56  (2.805) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      2  28.6%      7  77.8%      9  56.3% 
Male      5  71.4%      2  22.2%      7  43.8% 


  Outcome Measures

1.  Primary:   ACC Glx/Water   [ Time Frame: baseline and 10-weeks ]

2.  Primary:   ACC GABA/Water   [ Time Frame: baseline and 10-weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Vilma Gabbay
Organization: Icahn School of Medicine at Mount Sinai
phone: 212-659-1661
e-mail: vilma.gabbay@mssm.edu



Responsible Party: Vilma Gabbay, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT00962598     History of Changes
Other Study ID Numbers: GCO 12-1321
R21AT004576-01 ( U.S. NIH Grant/Contract )
First Submitted: August 19, 2009
First Posted: August 20, 2009
Results First Submitted: April 17, 2017
Results First Posted: May 24, 2017
Last Update Posted: April 24, 2018